Mathieu C, et al. - In patients with inadequately controlled type 1 diabetes (HbA1c ≥7.7 to ≤11.0% [≥61 to ≤97 mmol/mol]), researchers evaluated continuous glucose monitoring (CGM) in those who received dapagliflozin as an adjunct to adjustable insulin. The study sample consisted of 1,591 subjects who received dapagliflozin 5 mg (n=530), dapagliflozin 10 mg (n=529), or placebo (n=532). According to findings, treatment with dapagliflozin over 24 weeks improved time in range, mean glucose, and glycemic variability in patients with type 1 diabetes without increasing the time spent in the range indicating hypoglycemia.